Advertisement

Topics

Janssen’s Erleada wins FDA nod for nonmetastatic prostate cancer

01:14 EST 15 Feb 2018 | Pharmaceutical Business Review

Janssen Pharmaceutical’s androgen receptor inhibitor Erleada (apalutamide) has been approved by the US Food and Drug Administration (FDA) for the treatment of non-metastatic castration-resistant prostate cancer (NM-CRPC).

Original Article: Janssen’s Erleada wins FDA nod for nonmetastatic prostate cancer

NEXT ARTICLE

More From BioPortfolio on "Janssen’s Erleada wins FDA nod for nonmetastatic prostate cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Prostate Cancer
Prostate cancer (cancer de prostata) Prostate cancer (cancer de prostata) is a form of cancer that develops in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, there are cases of aggressive prostat...